Cancer Communications
indexed by SCI

About the cover
About the cover

Jul. 2015; Volume 34 Issue 7

In July 2000, the US FDA approved tamoxifen to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Tamoxifen is the first medication to be approved for DCIS, which accounts for nearly 20 percent of all newly diagnosed breast cancer cases. From The Coming Cancer Breakthroughs.

Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Xiao Xu
[ Abstract  1637]  [ PDF Full-text  2045]   [ HTML Full-text  1098]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0029-3
Original Article
Insight into early-phase trials for lung cancer in the United States
Jin-Ji Yang and Yi-Long Wu
[ Abstract  1223]  [ PDF Full-text  1533]   [ HTML Full-text  1174]    Epub: 2015-7-11  doi: 10.1186/s40880-015-0027-5
Predictive biomarkers in precision medicine and drug development against lung cancer
Bingliang Fang, Reza J Mehran, John V Heymach and Stephen G Swisher
[ Abstract  1221]  [ PDF Full-text  1457]   [ HTML Full-text  1093]    Epub: 2015-7-3  doi: 10.1186/s40880-015-0028-4
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Fei Zhou and Cai-Cun Zhou
[ Abstract  1138]  [ PDF Full-text  1281]   [ HTML Full-text  1099]    Epub: 2015-7-18  doi: 10.1186/s40880-015-0036-4
Global efforts in conquering lung cancer in China
Li Yan and Li Xu
[ Abstract  1172]  [ PDF Full-text  1179]   [ HTML Full-text  1000]    Epub: 2015-7-28  doi: 10.1186/s40880-015-0034-6
Letter to the Editor
Early-Phase Oncology Research Training (EFFORT) program: a Hengrui-USCACA joint scholarship
Li Yan and Li Xu
[ Abstract  1559]  [ PDF Full-text  1492]   [ HTML Full-text  1209]    Epub: 2015-7-8  doi: 10.1186/s40880-015-0035-5

CJC Wechat 微信公众号



Editorial Manager

CC adopts Editorial Manager to manage its submissions from Dec.18, 2014


Reference style for  

 Reference Manager

Editorial Manager





Advanced search


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China